Aralez Pharma (ARLZ) Posts Wider Q4 Loss, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
March 13, 2018 7:00 AM EDT-4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016-
-Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016-
-Provides 2018 Full-Year Financial Guidance-
MISSISSAUGA, Ontario, March 13, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company")Â today announced financial results for the fourth quarter and year ended December 31, 2017. The Company also highlighted certain recent corporate and commercial updates and provided 2018 full-year financial guidance. All... More
